FDA: ‘No evidence’ 2nd Paxlovid course stops recurring symptoms

An FDA official said there is currently no evidence a longer course of Pfizer's COVID-19 antiviral treatment would benefit patients experiencing a rebound in symptoms.

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive